title: [Adjuvant M-VEC in advanced urotheliomas of the bladder].
abstract: The therapeutic efficacy of chemotherapy in bladder's carcinoma is today supported by many statistical reports; the response rates are ranging from 35% to 45%. Results of the treatment with adjuvant chemotherapy (M-VEC in 22 patients with or without metastatic tumor are presented. Favourable objective responses were seen in 25% of the patients. The conclusion is drawn that this therapy is very useful in the treatment of metastatic diseases, but it can be used also in non-metastatic (M0) patients to prevent the growth of micrometastasis.
authors.forename: V
authors.initials: V
authors.lastname: Cocimano
authors.forename: G
authors.initials: G
authors.lastname: Marino
authors.forename: R
authors.initials: R
authors.lastname: Brigato
authors.forename: N
authors.initials: N
authors.lastname: Pacilli
authors.forename: G
authors.initials: G
authors.lastname: Buffa
authors.forename: R
authors.initials: R
authors.lastname: Marten Perolino
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015653:Cystectomy; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D015251:Epirubicin; D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate
vernacular_title: M-VEC adiuvante negli uroteliomi avanzati della vescica.